文献速递认知障碍与痴呆

血浆p-tau217与p-tau217/Aβ42在阿尔茨海默病中的横断面和纵向诊断效能

Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Aβ42 in Alzheimer's Disease.
PubMed 文献 · Ann Neurol · 2026-08-14

研究纳入ADNI的326名参与者和中国大湾区健康老龄化脑研究的357名老年人,评估血浆p-tau217单独或联合Aβ42对Aβ-PET阳性的诊断效能。结果显示p-tau217/Aβ42较p-tau217单独与Aβ-PET阳性一致性更强,可减少中间带,纵向监测有助于识别基线阴性或中间而后续Aβ-PET阳性者。

要点

  • p-tau217/Aβ42较p-tau217单独与Aβ-PET阳性一致性更强。
  • 联合Aβ42或Aβ42/40比值可减少诊断中间带。
  • 纵向p-tau217/Aβ42监测有助于识别基线误判为低风险的Aβ-PET阳性者。

核心结论

  • 血浆p-tau217/Aβ42可减少中间带并提高与Aβ-PET阳性的一致性。
  • 纵向p-tau217/Aβ42监测对识别基线阴性或中间而后续Aβ-PET阳性者尤其有价值。

研究设计与样本

  • 纳入ADNI的326名参与者和中国大湾区健康老龄化脑研究的357名老年人,均接受Aβ-PET成像。
  • ADNI中285名参与者有纵向数据,血浆p-tau181、p-tau217、Aβ42和Aβ40在不同分析平台检测。
  • 采用双截断值方法评估对Aβ-PET阳性的诊断效能。

主要发现

  • p-tau217/Aβ42阳性但p-tau217中间者中,57.1%至83.3%为Aβ-PET阳性。
  • 由p-tau217或p-tau217/Aβ42定义的稳定阳性者中88.0%至96.1%为Aβ-PET阳性。
  • 稳定阴性者中89.4%至90.9%为Aβ-PET阴性。
  • 由p-tau217/Aβ42定义的非阳性转为阳性者中,69.7%至75.8%为Aβ-PET阳性。

临床怎么用

  • 可考虑将血浆p-tau217/Aβ42用于AD的辅助诊断,以减少不确定的中间结果。
  • 对基线p-tau217/Aβ42阴性或中间者,纵向监测有助于发现后续Aβ-PET阳性患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent studies suggest that combining plasma phosphorylated tau (p-tau) with β-amyloid (Aβ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross-sectional and longitudinal concordance of these markers with Aβ positron emission tomography (PET) positivity remains incompletely understood. This study aimed to evaluate the diagnostic performance of plasma p-tau, alone and in combination with plasma Aβ, in AD. METHODS: We included 326 participants from the Alzheimer's Disease Neuroimaging Initiative and 357 Chinese older adults from the Greater-Bay-Area Healthy Aging Brain Study who underwent Aβ-PET imaging. Longitudinal data were available for 285 Alzheimer's Disease Neuroimaging Initiative participants. Plasma p-tau181, p-tau217, Aβ42, and Aβ40 were measured on different analytical platforms. Diagnostic performance for Aβ-PET positivity was assessed using a two-cutoff approach. RESULTS: Combining plasma p-tau with Aβ42 or the Aβ42/40 ratio reduced the intermediate zone. Notably, p-tau217/Aβ42 showed stronger agreement with Aβ-PET positivity than p-tau217 alone. Among individuals classified as p-tau217/Aβ42 positive but p-tau217 intermediate, 57.1 to 83.3% were Aβ-PET positive. Longitudinally, most Stable Positive (88.0-96.1%) and Stable Negative (89.4-90.9%) cases defined by p-tau217 or p-tau217/Aβ42 were Aβ-PET positive and Aβ-PET negative, respectively. Critically, 69.7 to 75.8% of Non-positive to Positive cases defined by p-tau217/Aβ42 were Aβ-PET positive. INTERPRETATION: These findings provide novel insights into the cross-sectional and longitudinal diagnostic performance of plasma p-tau217/Aβ42 in AD. To be specific, plasma p-tau217/Aβ42 can reduce the intermediate zone and improve agreement with Aβ-PET positivity, and longitudinal p-tau217/Aβ42 monitoring is particularly informative for identifying Aβ-PET-positive patients who were p-tau217/Aβ42 negative or intermediate at baseline and were misclassified as low risk of AD. ANN NEUROL 2026;100:998-1011.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Jiang M, Lan G, Zhu J, et al. Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Aβ42 in Alzheimer's Disease. Ann Neurol. 2026. PMID: 42601653. doi:10.1002/ana.78322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。